RemeGen has announced a clinical trial and supply agreement with Innovent Biologics.
The collaboration between RemeGen and Innovent Biologics focuses on conducting clinical trials to explore combination therapies using the novel antibody-drug conjugates (ADCs), RC88 and RC108, along with the PD-1 inhibitor sintilimab injection (TYVYT
